Companies appear wary of developing drugs for gram-negative bacteria

02/28/2010 | New York Times (tiered subscription model), The

Treatments for gram-negative bacteria are rarely pursued by drugmakers because of the bacteria's drug resistance, according to The New York Times. The lack of drugs also stems from the reluctance of developers to invest in antibiotics. The few candidates against gram-negative infection have increased in value, and big companies are licensing them from Calixa Therapeutics and other smaller firms.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ